11 jan: Indre værdi af SmallCap Danmark A/S er opgjort til 84,0 kr. pr. a..
11 jan: Danish Crown køber tysk slagteri
11-01-2017 07:59:53

Interim report Q1 - 1 September 2016 - 30 November 2016

Relateret indhold
16 feb - 
Nestlés vækst skuffer ledelsen og aktiemarkedet
15 feb - 
Aktier/tendens: Stigninger i vente - finansaktier og Ge..
15 feb - 
Chr. Hansen-rival sparer sig til højere indtjening
Relateret debat
20 feb - 
Mange mange tak
20 feb - 
PURE, HBIO, ROKA, PLSE, PACB
20 feb - 
Hvilke andre firmaer arbejder med samme forretningsområ..

Hoersholm, 2017-01-11 07:59 CET (GLOBE NEWSWIRE) --

 

Strong organic revenue growth of 11% in Q1 2016/17: Food Cultures & Enzymes (10%), Health & Nutrition (8%) and Natural Colors (13%). EBIT before special items increased by 21% to EUR 66 million.

 

EUR million

Q1

2016/17

Q1

2015/16

Growth

 

 

 

 

Revenue

  241.7

  214.4

13%

EBIT before special items

 65.5

54.0

21%

Profit for the period

47.0

 38.9

21%

Free cash flow before acquisitions, divestments and special items

  (19.1)

  (16.6)

(15)%

 

 

 

 

Organic growth, %

11%

14%

 

Gross margin, %

53.4%

52.3%

 

EBIT margin before special items, %

27.1%

25.2%

 

ROIC excl. goodwill, %

34.3%

33.1%

 

 

“The results in Q1 gave us a good start to the year, and we maintain our guidance for the full year. Both Food Cultures & Enzymes and Natural Colors delivered strong organic growth and improved profitability. The organic growth in Health & Nutrition was still below our long-term ambitions, however, better than expected for the quarter, mainly due to timing of orders. The EBIT margin for the business area was down, partly due to an unfavorable product mix,” says CEO Cees de Jong.

“We made good progress on our focus areas for 2016/17. Our bioprotective cultures continue to deliver strong growth. In Q1, growth was approximately 25%, and the segment now accounts for approximately 5% of the revenue in Food Cultures & Enzymes. In November, we concluded the acquisition of LGG®, and we have initiated integrating the business into Chr. Hansen. The integration of NPC is being concluded and we are starting to reap the synergies from the acquisition. Plant health supported the growth in Health & Nutrition with sales of both Nemix® C and VGR™, and we are making progress in our work to introduce new products in the coming years. Natural Colors showed good progress in Q1.”

 

OUTLOOK FOR 2016/17                                                                   

The outlook for 2016/17 is unchanged compared to the announcement of 26 October 2016.

Organic revenue growth: 8-10% (previously 8-10%)

EBIT margin before special items: slightly increasing (previously slightly increasing)

Free cash flow before acquisitions, divestments and special items:

around EUR 175 million (previously around EUR 175 million)

 

This unaudited interim report has been prepared in accordance with IAS 34 and additional Danish regulations. The interim report has been prepared in accordance with the accounting policies set out in the Annual Report for 2015/16.

 

For further information, please contact:

Cees de Jong, CEO

Tel: +45 4574 7474

Søren Westh Lonning, CFO

Tel: +45 4574 7474

Anders Mohr Christensen, Senior Director, Investor Relations

Tel: +45 4574 7618

 

Forward-looking statements

This announcement contains forward-looking statements. Such statements are subject to risks and uncertainties, as various factors, many of which are beyond the control of Chr. Hansen Holding A/S, may cause actual developments and results to differ materially from the expectations expressed in this announcement.

 

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2015/16 financial year was EUR 949 million. The company has more than 2,700 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen A/S. For further information, please visit www.chr-hansen.com.

Vedhæftet fil: Company announcement Q1.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Rovsing mindsker driftsunderskud i første halvår og opjusterer

24-02-2017 16:36:15
Omsætningen i Rovsing, der har hovedkontor i Skovlunde ved København og blandt andet producerer testsystemer til satellitter og elektroniske produkter til rumin..

KORR. Genmab/Sydbank: Positiv anbefaling er godt nyt - og ventet

24-02-2017 14:04:12
(Korr: "uger" rettet til "måneder" i sjette afsnit)Det europæiske lægemiddelagenturs (EMA) komite for medicinske produkter for human anvendelse (CHMP) har givet..

Aktier/middag: Mærsk og Genmab i C20-bunden og dukkert til Rockwool

24-02-2017 11:44:51
Trods yderligere fremgang til ISS, der torsdag leverede et stærkt regnskab, ligger det danske aktiemarked fredag middag i et minus efter fald i aktier som Mærsk..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Chr Hansen Holding A/S 415,20 -0,4% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. februar 2017 20:03:08
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170217.2 - EUROWEB5 - 2017-02-26 20:03:08 - 2017-02-26 20:03:08 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x